260 related articles for article (PubMed ID: 33543755)
1. There Is Life After the UK Clozapine Central Non-Rechallenge Database.
Oloyede E; Casetta C; Dzahini O; Segev A; Gaughran F; Shergill S; Mijovic A; Helthuis M; Whiskey E; MacCabe JH; Taylor D
Schizophr Bull; 2021 Jul; 47(4):1088-1098. PubMed ID: 33543755
[TBL] [Abstract][Full Text] [Related]
2. Relaxation of the criteria for entry to the UK Clozapine Central Non-Rechallenge Database: a modelling study.
Oloyede E; Whiskey E; Casetta C; Dzahini O; Dunnett D; Gandhi S; Gaughran F; Shergill S; McGuire P; MacCabe JH; Taylor D
Lancet Psychiatry; 2022 Aug; 9(8):636-644. PubMed ID: 35772414
[TBL] [Abstract][Full Text] [Related]
3. Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals.
Oloyede E; Dzahini O; Barnes N; Mijovic A; Gandhi S; Stuart-Smith S; de Witte T; Taylor D; Whiskey E
BMC Psychiatry; 2021 Oct; 21(1):502. PubMed ID: 34645395
[TBL] [Abstract][Full Text] [Related]
4. Clozapine rechallenge following neutropenia using granulocyte colony-stimulating factor: A Quebec case series.
Béchard L; Corbeil O; Plante M; Thivierge MA; Lafrenière CÉ; Roy MA; Demers MF
J Psychopharmacol; 2021 Sep; 35(9):1152-1157. PubMed ID: 34229529
[TBL] [Abstract][Full Text] [Related]
5. Evaluating the Effect of the Changes in FDA Guidelines for Clozapine Monitoring.
Sultan RS; Olfson M; Correll CU; Duncan EJ
J Clin Psychiatry; 2017; 78(8):e933-e939. PubMed ID: 28742291
[TBL] [Abstract][Full Text] [Related]
6. [Clozapine rechallenge after neutropenia in resistant schizophrenia: A review].
Simon L; Cazard F
Encephale; 2016 Aug; 42(4):346-53. PubMed ID: 27109327
[TBL] [Abstract][Full Text] [Related]
7. Clozapine Rechallenge After Major Adverse Effects: Clinical Guidelines Based on 259 Cases.
Manu P; Lapitskaya Y; Shaikh A; Nielsen J
Am J Ther; 2018; 25(2):e218-e223. PubMed ID: 29505490
[TBL] [Abstract][Full Text] [Related]
8. Lithium and clozapine rechallenge: a retrospective case analysis.
Kanaan RA; Kerwin RW
J Clin Psychiatry; 2006 May; 67(5):756-60. PubMed ID: 16841625
[TBL] [Abstract][Full Text] [Related]
9. Rechallenge with clozapine following leucopenia or neutropenia during previous therapy.
Dunk LR; Annan LJ; Andrews CD
Br J Psychiatry; 2006 Mar; 188():255-63. PubMed ID: 16507968
[TBL] [Abstract][Full Text] [Related]
10. Successful Clozapine Rechallenge After Clozapine-Induced Severe Anemia: A Case Report.
Barros FMR; Tolentino AC; Marques LSK; Schlittler LXC; Oliveira KD; Dalgalarrondo P; Barnes LL; Dos Santos Junior A; Banzato CEM
Schizophr Bull; 2024 Apr; 50(3):717-719. PubMed ID: 38502910
[TBL] [Abstract][Full Text] [Related]
11. Clozapine Response in Schizophrenia and Hematological Changes.
Blackman G; Lisshammar JEL; Zafar R; Pollak TA; Pritchard M; Cullen AE; Rogers J; Carter B; Griffiths K; Nour M; David AS; McGuire P; Stewart R; MacCabe J
J Clin Psychopharmacol; 2021 Jan/Feb 01; 41(1):19-24. PubMed ID: 33347018
[TBL] [Abstract][Full Text] [Related]
12. Effects on monotherapy and reduction of antipsychotic drugs by clozapine therapy in Japanese patients with treatment-resistant schizophrenia.
Akamine Y; Kikuchi Y; Miura M
J Clin Pharm Ther; 2021 Oct; 46(5):1312-1318. PubMed ID: 33959995
[TBL] [Abstract][Full Text] [Related]
13. Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis.
Meyer N; Gee S; Whiskey E; Taylor D; Mijovic A; Gaughran F; Shergill S; MacCabe JH
J Clin Psychiatry; 2015 Nov; 76(11):e1410-6. PubMed ID: 26646037
[TBL] [Abstract][Full Text] [Related]
14. When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature.
Manu P; Sarpal D; Muir O; Kane JM; Correll CU
Schizophr Res; 2012 Feb; 134(2-3):180-6. PubMed ID: 22113154
[TBL] [Abstract][Full Text] [Related]
15. Clozapine Rechallenge After Neutropenia or Leucopenia.
Prokopez CR; Armesto AR; Gil Aguer MF; Balda MV; Papale RM; Bignone IM; Daray FM
J Clin Psychopharmacol; 2016 Aug; 36(4):377-80. PubMed ID: 27232877
[TBL] [Abstract][Full Text] [Related]
16. Clozapine Rechallenge or Continuation Despite Neutropenia, an Extended Follow-up of a Consecutive Quebec Case Series.
Béchard L; Morasse-Bégis M; Corbeil O; Hakim JR; Malenfant E; Brodeur S; Huot-Lavoie M; Essiambre AM; Demers MF; Roy MA
J Clin Psychopharmacol; 2022 Jul-Aug 01; 42(4):391-395. PubMed ID: 35546087
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes after Clozapine Discontinuation in Patients with Schizophrenia: A Systematic Review.
Miura G; Tanaka K; Kemuriyama T; Misawa F; Uchida H; Mimura M; Takeuchi H
Pharmacopsychiatry; 2022 Jul; 55(4):181-192. PubMed ID: 35512817
[TBL] [Abstract][Full Text] [Related]
18. Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study.
Grover S; Chaurasiya N; Chakrabarti S
J Clin Psychopharmacol; 2023 Sep-Oct 01; 43(5):403-406. PubMed ID: 37683227
[TBL] [Abstract][Full Text] [Related]
19. Clozapine re-challenge under the cover of Filgrastim.
Gopalakrishnan R; Subhalakshmi TP; Kuruvilla A; Jacob KS
J Postgrad Med; 2013; 59(1):54-5. PubMed ID: 23525060
[TBL] [Abstract][Full Text] [Related]
20. The Effect of Clozapine on Hematological Indices: A 1-Year Follow-Up Study.
Lee J; Takeuchi H; Fervaha G; Powell V; Bhaloo A; Bies R; Remington G
J Clin Psychopharmacol; 2015 Oct; 35(5):510-6. PubMed ID: 26267420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
